Abstract
Plasma substitutes, such as crystalloid or colloid solutions are frequently used in bleeding patients or in situations with a high risk of bleeding such as trauma or during surgery. There is ample evidence that these agents may affect blood coagulation and platelet function [1], although some authors, referring to thromboelastography studies, have suggested that hemodilution per se results in a hypercoagulable state [2]. These findings, however, have been disputed. In particular, all three distinct classes of artificial colloids (i.e., dextrans, hydroxyethyl starches [HES], and gelatins) have been associated with derangements of the hemostatic system, although the clinical significance of these derangements is a matter of debate [3]. In this chapter, we will focus on the anti-hemostatic effects of various volume replacement fluids on platelet function and blood coagulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
de Jonge E, Levi M (2001) Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 29:1261–1267
Ruttmann TG, James MF, Aronson I (1998) In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 80:612–616
Salmon JB, Mythen MG (1993) Pharmacology and physiology of colloids. Blood Rev 7:114–120
Clagett GP, Anderson FA Jr, Heit J, Levine M, Wheeler HB (1995) Prevention of venous thromboembolism. Chest 108:312S–334S
Batlle J, del Rio F, Lopez Fernandez MF, Martin R, Lopez BA (1985) Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost 54:697–699
Zhang B, Wieslander JB (1993) Dextran’s antithrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: an experimental study. Microsurgery 14:289–295
Bergman A, Andreen M, Blomback M (1990) Plasma substitution with 3% dextran-60 in orthopaedic surgery: influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents. Acta Anaesthesiol Scand 34:21–29
Lethagen S, Rugarn P, Aberg M, Nilsson IM (1990) Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand 156: 597–602
Eriksson M, Saldeen T (1995) Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) during surgery. Acta Anaesthesiol Scand 39:163–166
Carr ME, Gabriel DA (1980) The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 96:985–993
Hjertberg H, Olsson J, Ekstrom T, Lisander B (1996) Do low molecular weight heparin and dextran increase the blood loss in transurethral resection of the prostate? Br J Urol 78:897–900
Bergqvist D, Kettunen K, Fredin H, et al (1991) Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery 109:617–622
Lisander B, Jacobsson SA, Ivarsson I, Vegfors M, Engdahl O (1996) Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty. Eur J Surg 162:861–866
Lundsgaard-Hansen P, Tschirren B (1980) Clinical experience with 120,000 units of modified fluid gelatin. Dev Biol Stand 48:251–256
Mardel SN, Saunders FM, Allen H, et al (1998) Reduced quality of clot formation with gelatin-based plasma substitutes. Br J Anaesth 80:204–207
Ruttmann TG, James MF, Viljoen JF (1996) Haemodilution induces a hypercoagulable state. Br J Anaesth 76:412–414
Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oeveren W (1995) Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 74:1447–1451
de Jonge E, Levi M, Berends F, van der Ende AE, ten Cate JW, Stoutenbeek CP (1998) Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 79:286–290
Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G (1993) Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185–1190
Dalrymple-Hay M, Aitchison R, Collins P, Sekhar M, Colvin B (1992) Hydroxyethyl starch induced acquired von Willebrand’s disease. Clin Lab Haematol 14:209–211
Damon L, Adams M, Stricker RB, Ries C (1987) Intracranial bleeding during treatment with hydroxyethyl starch. N Engl J Med 317:964–965
Cope JT, Banks D, Mauney MC, et al (1997) Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann Thorac Surg 63:78–82
Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R (1985) Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 25:349–354
Kapiotis S, Quehenberger P, Eichler HG, et al (1994) Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin. Crit Care Med 22:606–612
Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra PW, van Oeveren W (1997) Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Eur J Cardiothorac Surg 11:626–632
Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K (1996) All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 36:450–455
de Jonge E, Levi M, Buller R, Berends F, Kesecioglu J (2001) Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 27:1825–1829
Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH (1989) Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 17:394–398
Strauss RG, Stump DC, Henriksen RA, Saunders R (1985) Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 25:230–234
Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR (1997) Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth 78:684–689
Boldt J, Muller M, Heesen M, Heyn O, Hempelmann G (1996) Influence of different volume therapies on platelet function in the critically ill. Intensive Care Med 22:1075–1081
Mortelmans YJ, Vermaut G, Verbruggen AM, et al (1995) Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg 81:1235–1242
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science + Business Media Inc.
About this paper
Cite this paper
Levi, M., de Jonge, E. (2006). Effects of Plasma Substitutes on Coagulation. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/0-387-35096-9_26
Download citation
DOI: https://doi.org/10.1007/0-387-35096-9_26
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-30156-3
Online ISBN: 978-0-387-35096-7
eBook Packages: MedicineMedicine (R0)